STOK · NASDAQ
Stoke Therapeutics, Inc.
$26.32 +0.34 (+1.30%)
Company overview
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform to design ASOs that precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in a Phase I/IIa clinical trial for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in the preclinical stage for autosomal dominant optic atrophy. The company has entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $1.7B
- Employees
- 128
- Headquarters
- Bedford, MA
- Website
- stoketherapeutics.com
- CEO
- Ian F. Smith
- Listed
- June 19, 2019
- P/E
- -9.30
- Dividend yield
- 0.00%
Company financials
- Revenue
- $32.1M
- Gross profit
- $29M
- Operating income
- -$185M
- EBITDA
- -$178M
- Net income
- -$170M
- EPS
- -$2.83
- Total assets
- $443M
- Total debt
- $3.4M
- Gross margin
- 90.36%
- Net margin
- -529.20%
- Earnings yield
- -10.75%
No geographic segmentation.
Showing FY 2025
STOK
1D
NASDAQ
O26.54H26.98L26.03C26.32-0.09 (-0.36%)Vol144.97K